Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of JY09 in Healthy Subjects
NCT04354090Phase 1Completed
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JY-09 in type 2 diabetes mellitus (T2DM) (5 cohorts), sponsored by Beijing Dongfang Biotech Co., Ltd. Primary endpoint: Incidence of adverse events and serious adverse events related to JY09. Started Apr 2018; status: completed.
02
Drugs
JY-09
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04354090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354090.